SGN-40

SGN-40 (also known as denintuzumab mafodotin or SGN-CD40M) is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Seattle Genetics.

Mechanism of Action

SGN-40 is a monoclonal antibody that targets the CD40 molecule, which is overexpressed in many types of B-cell malignancies. The antibody is linked to a potent cytotoxic agent, monomethyl auristatin F (MMAF), which is released inside the cancer cell after the antibody binds to the CD40 molecule. This leads to the death of the cancer cell.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of SGN-40. These trials have included patients with non-Hodgkin lymphoma, multiple myeloma, and chronic lymphocytic leukemia. The results of these trials have shown that SGN-40 can induce responses in a significant proportion of patients, even those with advanced disease.

Side Effects

The most common side effects of SGN-40 include fatigue, nausea, and diarrhea. Less common side effects include neutropenia, anemia, and thrombocytopenia. In some cases, these side effects can be severe and may require dose reductions or discontinuation of treatment.

Future Directions

Research is ongoing to further evaluate the potential of SGN-40 in the treatment of B-cell malignancies. This includes studies to determine the optimal dosing schedule and to evaluate the drug in combination with other treatments.

SGN-40 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia